The global hypertrophic cardiomyopathy (HCM) therapeutics market is estimated to grow at a CAGR of nearly 1.5% during the forecast period. The significant prevalence of CVD is the major factor contributing to the market growth. As per the World Health Organization (WHO), CVDs are the major cause of mortality across the globe. In 2016, CVD accounted for nearly 17.9 million mortalities, which represented 31% of all global mortalities. 85% of these mortalities were reported due to stroke and heart attack. HCM is a genetic cardiac disease, which occurs due to the increase in wall thickness of left ventricle. It is usually caused by abnormal genes in the heart muscle, which cause left ventricle walls to become thicker and harder than normal.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/hypertrophic-cardiomyopathy-hcm-therapeutics-market
Each child of a person with HCM has a 50% chance of inheriting the condition. In UK, nearly 1 in 500 people have the condition, however, most people who are suffering from this condition have few symptoms. The objective of HCM treatment is to provide relief from symptoms and avoid sudden cardiac death in people who are at high risk. Medications can support to slow the heart rate that facilitates the heart to pump blood better. The medications that are used for the treatment of HCM and its symptoms may comprise calcium channel blockers, beta-blockers, antiarrhythmic drugs, and anticoagulants. However, these medications have certain side-effects that may comprise low blood pressure and fluid in the lungs and in some cases, certain medications may cause sudden death. The increasing demand for surgeries such as septal myectomy, septal ablation, heart transplant, and implantable cardioverter defibrillator, to treat HCM is further expected to hinder the market growth
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/hypertrophic-cardiomyopathy-hcm-therapeutics-market
Market Segmentation
Global HCM Therapeutics Market by Drug Class
• Beta Adrenergic Blocking Agents
• Anticoagulants
• Antiarrhythmic Agents
• Calcium Channel Blockers
• Others
Regional Analysis
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World

Company Profiles
• ANI Pharmaceuticals, Inc.
• AstraZeneca plc
• Bayer AG
• Bristol Myers Squibb Co.
• Cipla Ltd.
• General Electric Co.
• Gilead Sciences, Inc.
• Lannett Co., Inc.
• Merck & Co., Inc.
• Mylan N.V.
• MyoKardia, Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hypertrophic-cardiomyopathy-hcm-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404